Congo Ebola Outbreak Passes 10,000 Cases as Fears Grow Over Wider African Spread

Democratic Republic of the Congo's Ebola outbreak has crossed a threshold. The country's National Institute of Public Health reported 10,060 confirmed cases and 4,887 deaths as of October 25, 2026, a case fatality rate of 48.6 percent. The outbreak is driven by the Bundibugyo virus, a rare Ebola species for which no vaccine or treatment has been approved. The milestone makes the epidemic the second-largest Ebola outbreak on record, behind only the 2014 to 2016 West African epidemic.

The outbreak was announced in mid-May 2026 and was first detected in Ituri, in northeastern Congo. It is the country's 17th Ebola outbreak and has already become the largest and deadliest in its history, surpassing the 2018 to 2020 epidemic. Ituri and North Kivu account for most reported cases. North Kivu is partly controlled by the Rwanda-backed M23 militia. The WHO said on October 23 that 66 health zones in eight of Congo's 26 provinces had reported cases.

Ebola spreads through direct contact with the blood or other bodily fluids of an infected person. It can cause fever, diarrhea and, in some cases, bleeding. Early symptoms can resemble malaria, which can delay isolation and treatment. Those facts matter because the Bundibugyo species has no approved vaccine or treatment. Experimental trials are under way, but they are still at the research stage.

The geographic spread has widened concerns beyond Congo. Kenya, which had not reported a single case until October 6, has recorded nine infections and two deaths. Nigeria has confirmed an imported case in a Swiss woman, the wife of a Swiss diplomat, who fell ill after visiting Uganda. Uganda reported 20 cases and two deaths in May and June, mostly imported from Congo, and was declared Ebola-free in late August. The WHO has warned that Africa faces a complex task in containing an outbreak spanning the east, west and centre of the continent.

Key Facts

Reuters reported on October 27, 2026, that Congo's confirmed Ebola cases had risen above 10,000, with government data putting the total at 10,060 cases and 4,887 deaths. The news agency said the outbreak had become the largest and deadliest in Congo's history and the second-largest and second-deadliest on record. Only the 2014 to 2016 West African outbreak ranks higher, with more than 28,600 infections and more than 11,000 deaths.

AFP reported on October 27, 2026, that the outbreak had passed 10,000 confirmed cases, almost all of them in Congo, with almost 5,000 fatalities. The agency said 2,684 people had recovered in Congo and that the fatality rate appeared to be close to 50 percent. It also noted that the virus was first detected in Ituri and that the country was experiencing its 17th outbreak.

The World Health Organization reported on October 23, 2026, that 9,704 confirmed cases and 4,687 deaths had been recorded as of October 20, a crude case fatality ratio of 48.3 percent. The agency said 976 confirmed cases and 482 confirmed deaths had been added since its previous update on October 8. Of those 482 deaths, 307 occurred in communities and 175 in treatment centres. Ituri remained the epicentre with 7,040 cases and 3,271 deaths. North Kivu followed with 2,146 cases and 1,199 deaths, and it had the highest provincial case fatality ratio at 55.9 percent.

Contact tracing remains below the standard required to stop transmission. The WHO said 30,130 contacts were under follow-up across six provinces, and 24,017 had been seen in the previous 24 hours, a follow-up rate of 79.7 percent. North Kivu had the weakest performance at 73.3 percent. Kenya had nine cases, including one death as of October 20, all linked to a single imported index case. Nigeria confirmed an imported case in Abuja on October 20, and 44 contacts were being monitored.

DW reported on October 27, 2026, that the Africa Centres for Disease Control and Prevention had described the outbreak as the fastest-growing Ebola outbreak in history. The outlet also reported that clinical trials of two antiviral treatment approaches had been under way since July, and that two further trials were investigating whether the Ervebo vaccine can protect against Bundibugyo virus. Ervebo is approved only against the Zaire virus. On October 23, the TUMAINI vaccine trial was launched, with the first participants enrolled in Bunia.

Analysis

The most important number in this outbreak may not be the 10,060 confirmed cases. It may be the 48.6 percent case fatality rate. A virus that kills one of every two confirmed patients is not simply a severe emergency. It is a signal that detection, isolation and treatment are arriving too late for many patients. The WHO's breakdown makes that clear. Of 482 deaths reported in one recent period, 307 occurred in communities rather than in treatment centres. That pattern points to delays in early case detection and access to care.

The bigger picture here is that the world's Ebola toolkit is not evenly built. The licensed vaccine Ervebo is approved only against the Zaire virus. Bundibugyo is a different species, and it has no approved vaccine or specific treatment. The Ervebo trials are an attempt to test whether a licensed Zaire vaccine can be repurposed, but they are experiments, not a ready answer. The trials are beginning in an epidemic that has already infected more than 10,000 people. Research is catching up to an outbreak that needed proven tools at the start.

The response is also being shaped by geography and security. Ituri is the epicentre, with 7,040 cases and 3,271 deaths as of October 20. North Kivu, which has 2,146 cases, has the highest provincial fatality rate at 55.9 percent and is partly controlled by the Rwanda-backed M23 militia. Those conditions make contact tracing harder. The overall follow-up rate of 79.7 percent is far below the 95 percent threshold, and North Kivu's rate is 73.3 percent. When fewer than four in five contacts are seen within a day, chains of transmission can continue unnoticed.

The cross-border cases have turned a national emergency into a regional test. Kenya's nine cases and two deaths are linked to a traveler who moved from Congo through Uganda to Nairobi. Nigeria's imported case involved a Swiss woman who had not traveled to Congo and was believed to have contracted the virus in Uganda, according to the Swiss government. She and her husband were flown to hospitals in Switzerland on Monday. Uganda said citizens returning with a history of travel to Congo would be quarantined for 21 days.

Why It Matters

The outbreak matters because it is now the second-largest Ebola epidemic ever recorded, and it is still growing. The 2014 to 2016 West African epidemic infected more than 28,600 people and killed more than 11,000. The Africa CDC's description of it as the fastest-growing Ebola outbreak in history is a warning about speed, not just size. The longer the virus circulates, the more opportunities it has to reach new communities and new countries.

The absence of an approved Bundibugyo vaccine or treatment changes the calculus for health workers and governments. For Bundibugyo, those tools are still in trials. That gap increases the weight carried by basic public health measures: finding cases, isolating patients and tracing contacts. A follow-up rate below 95 percent is not a technical detail. It is a measure of how many possible next infections are being missed.

The security dimension makes the outbreak harder to contain and more dangerous for local health staff. AFP reported on October 27, 2026, that a nurse was killed and a health worker seriously wounded in Tshopo province on Saturday. Young people accused the victims of trying to infect locals with tablets before attacking them, according to Dr Marcel Likolo, chief medical officer of the Bafwasende health district. The Ebola treatment centre has since shut down. Such attacks remove care capacity and deepen mistrust.

Next Up

The immediate priority is to close the contact tracing gap and accelerate the trials already under way. The TUMAINI vaccine trial, launched on October 23 with first participants in Bunia, will be watched for early signals about whether an existing vaccine platform can work against Bundibugyo. The two antiviral treatment approaches that began in July, and the two Ervebo trials, are the other near-term sources of evidence. Until those studies produce results, responders have to rely on detection, isolation and care.

Regional surveillance will be the other test. Kenya, Nigeria and Uganda are now part of the investigation, and the WHO has advised against restrictions on travel or trade with affected countries. The coming weeks will show whether the cross-border cases remain limited or whether the outbreak establishes new chains of transmission outside Congo. For now, the epidemic has already outgrown the tools designed for a different Ebola virus.